Sumant Kulkarni Analyst PerformanceManaging Director, Biotech Research Analyst at Canaccord Genuity GroupSumant Kulkarni is a stock analyst at Canaccord Genuity Group focused in the medical sector, covering 20 publicly traded companies. Over the past year, Sumant Kulkarni has issued 28 stock ratings, including buy and hold recommendations. While full access to Sumant Kulkarni's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sumant Kulkarni's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings94 Last 10 YearsBuy Recommendations88.04% 81 Buy RatingsCompanies Covered20 Unique Companies Ratings Distribution92RatingsDistribution of strong buy, buy, hold, and sell ratings by Sumant Kulkarni.RatingPercentageCount Strong Buy0.0%0 ratings Buy88.0%81 ratings Hold12.0%11 ratings Sell0.0%0 ratingsOut of 92 total stock ratings issued by Sumant Kulkarni at Canaccord Genuity Group, the majority (88.0%) have been Buy recommendations, followed by 12.0% Hold.Best & Worst CallsBest Call0000.0%BTAIMar 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHCDec 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ85.0% of companies on NASDAQ17 companiesNYSE15.0% of companies on NYSE3 companiesSumant Kulkarni, an analyst at Canaccord Genuity Group, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical18 companies90.0%Manufacturing2 companies10.0%Sumant Kulkarni of Canaccord Genuity Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE12 companies60.0%MED - DRUGS2 companies10.0%Miscellaneous2 companies10.0%BIOTECHNOLOGY1 company5.0%MED - OUTP/HM CRE1 company5.0%MEDICAL SERVICES1 company5.0%MED - GENERIC DRG1 company5.0% Sumant Kulkarni's Ratings History at Canaccord Genuity Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsDFTXDefinium Therapeutics6/16/2026Reiterated Rating$23.76$38.00Buy$0.0000.00% ROIZVRAZevra Therapeutics6/9/2026Boost Price Target$13.28$29.00Buy$0.0000.00% ROIATAIAtai Beckley4/20/2026Boost Price Target$4.03$15.00Buy$0.0000.00% ROIDFTXDefinium Therapeutics4/16/2026Set Price Target$22.15$38.00Buy$0.0000.00% ROIANVSAnnovis Bio4/14/2026Reiterated Rating$1.71$17.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences4/7/2026Boost Price Target$129.75$200.00Buy$0.0000.00% ROIBIIBBiogen4/1/2026Boost Price Target$183.33$245.00Buy$0.0000.00% ROICMPSCompass Pathways3/26/2026Lower Price Target$5.75$18.00Buy$0.0000.00% ROISTOKStoke Therapeutics3/20/2026Boost Price Target$33.50$60.00Buy$0.0000.00% ROIMPLTMaplight Therapeutics3/19/2026Initiated Coverage$17.02$35.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CLNNClene3/13/2026Reiterated Rating$5.95$48.00Buy$0.0000.00% ROICMPSCompass Pathways2/18/2026Boost Price Target$8.58$20.00Buy$0.0000.00% ROIBIIBBiogen2/9/2026Boost Price Target$195.79$230.00Buy$0.0000.00% ROIGHRSGH Research1/6/2026Boost Price Target$15.46$39.00Buy$0.0000.00% ROISTOKStoke Therapeutics1/5/2026Boost Price Target$30.90$36.00Buy$0.0000.00% ROIDFTXDefinium Therapeutics11/7/2025Boost Price Target$11.70$25.00Buy$0.0000.00% ROIZVRAZevra Therapeutics11/6/2025Lower Price Target$8.89$24.00Buy$0.0000.00% ROISTOKStoke Therapeutics11/5/2025Boost Price Target$22.06$28.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences10/29/2025Boost Price Target$138.02$164.00Buy$0.0000.00% ROIATAIAtai Beckley10/22/2025Boost Price Target$5.73$14.00Buy$0.0000.00% ROIANVSAnnovis Bio9/30/2025Reiterated Rating$2.04$17.00Buy$0.0000.00% ROICLNNClene8/18/2025Lower Price Target$3.62$48.00Buy$0.0000.00% ROICMPSCompass Pathways8/1/2025Reiterated Rating$4.36$15.00Buy$0.0000.00% ROICRVOCervoMed7/29/2025Boost Price Target$8.55$27.00Buy$0.0000.00% ROIATAIAtai Beckley7/28/2025Lower Price Target$3.27$11.00Buy$0.0000.00% ROIHELPCybin7/8/2025Lower Price Target$7.62$70.00Buy$0.0000.00% ROIATAIAtai Beckley7/2/2025Boost Price Target$2.73$12.00Buy$0.0000.00% ROISAGESage Therapeutics6/17/2025Boost Price Target$9.07$8.50Hold$0.0000.00% ROIANVSAnnovis Bio5/15/2025Lower Price Target$1.71$17.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences5/6/2025Boost Price Target$109.75$160.00Buy$000.0000.00% ROIBIIBBiogen5/2/2025Lower Price Target$123.25$220.00Buy$000.0000.00% ROINBIXNeurocrine Biosciences4/28/2025Lower Price Target$106.73$158.00Buy$000.0000.00% ROICRVOCervoMed3/18/2025Boost Price Target$9.05$21.00Buy$0.0000.00% ROIZVRAZevra Therapeutics3/13/2025Boost Price Target$7.98$25.00Buy$00.0000.00% ROIVYGRVoyager Therapeutics3/13/2025Lower Price Target$4.03$12.00Buy$0.0000.00% ROICMPSCompass Pathways2/28/2025Lower Price Target$3.96$15.00Buy$0.0000.00% ROIBIIBBiogen2/13/2025Lower Price Target$133.43$265.00Buy$000.0000.00% ROISAGESage Therapeutics2/12/2025Lower Price Target$7.19$8.00Hold$0.0000.00% ROIHELPCybin2/12/2025Lower Price Target$9.39$73.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences2/7/2025Lower Price Target$124.12$163.00Buy$000.0000.00% ROIRead this warning immediately (Ad)Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.Read Porter Stansberry's full breakdown and protect your wealth now Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageThe Goldman Sachs GroupWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
